MaxCyte (MXCT) Projected to Announce Quarterly Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) is expected to be announcing its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $7.39 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%. The firm had revenue of $6.50 million for the quarter, compared to analyst estimates of $6.51 million. On average, analysts expect MaxCyte to post ($0.25) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

MaxCyte Stock Performance

MaxCyte stock traded down $0.04 during trading on Tuesday, reaching $1.41. The company had a trading volume of 296,638 shares, compared to its average volume of 1,051,224. The firm has a market capitalization of $145.00 million, a PE ratio of -4.26 and a beta of 1.49. The firm’s 50-day simple moving average is $1.26 and its 200 day simple moving average is $1.07. MaxCyte has a 1-year low of $0.64 and a 1-year high of $1.80.

Analyst Upgrades and Downgrades

MXCT has been the topic of several recent analyst reports. BTIG Research reaffirmed a “neutral” rating on shares of MaxCyte in a report on Monday, August 24th. Weiss Ratings raised shares of MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a life sciences company that develops technologies for engineering cells used in biopharmaceutical research and the development of cell-based therapies. Its platform is designed to help researchers modify cells efficiently for applications including cell therapy, gene editing, immuno-oncology and other advanced biological treatments.

The company’s primary offering is the ExPERT platform, which combines Flow Electroporation technology with specialized instruments, single-use processing assemblies, software and related support services.